CTIC.MI - CTI BioPharma Corp.

Milan - Milan Delayed Price. Currency in EUR
2.44
-0.02 (-0.81%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous Close2.46
Open2.44
Bid2.40 x 19700
Ask2.48 x 100000
Day's Range2.42 - 2.48
52 Week Range2.42 - 42.52
Volume0
Avg. Volume15,163
Market Cap105.461M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Is CTI BioPharma Corp (CTIC) Undervalued?
    Simply Wall St.4 days ago

    Is CTI BioPharma Corp (CTIC) Undervalued?

    CTI BioPharma Corp (NASDAQ:CTIC), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference
    PR Newswire16 days ago

    CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference

    SEATTLE , Nov. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the Jefferies 2017 London Healthcare Conference Wednesday, ...

  • Associated Press17 days ago

    CTI BioPharma reports 3Q loss

    The Seattle-based company said it had a loss of 28 cents per share. Losses, adjusted for stock option expense, came to 25 cents per share. The biotechnology company posted revenue of $1.7 million in the ...

  • Capital Cube24 days ago

    ETFs with exposure to CTI BioPharma Corp. : October 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-IT. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube25 days ago

    CTI BioPharma Corp. breached its 50 day moving average in a Bearish Manner : CTIC-IT : October 30, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for CTI BioPharma Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Capital Cubelast month

    CTI BioPharma Corp. – Value Analysis (MILAN:CTIC) : October 12, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives CTI BioPharma Corp. a score of 28. Our analysis is based on comparing CTI BioPharma Corp. with the following peers – NEL ASA, Neimeth International Pharmaceuticals PLC, Navamedic ASA and Neuron Bio S.A. (NEL-NO, NEIMETH-NG, NAVA-NO and NEU-ES). Investment Outlook CTI BioPharma Corp. has a fundamental score ... Read more (Read more...)

  • CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-IT : October 11, 2017
    Capital Cubelast month

    CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-IT : October 11, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for CTI BioPharma Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
    PR Newswire2 months ago

    CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions

    SEATTLE, Sept. 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed its new Chairman of the Board and the promotion of David H. Kirske to Chief Financial Officer and Bruce J. Seeley to Chief Operating Officer of the company. "The appointments announced today strengthen and solidify our board and leadership at an important time for the company," said Adam R. Craig, M.D., Ph.D., President and CEO of CTI BioPharma. "I am pleased to serve as Chairman as the changes taking place at the company provide the opportunity to deliver on the commitment to patients and shareholders," said Dr. Fischer.

  • PR Newswire3 months ago

    CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference

    SEATTLE , Aug. 31, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the 24th Annual BioCentury NewsMakers in the Biotech Industry ...

  • Associated Press4 months ago

    CTI BioPharma posts 2Q profit

    The Seattle-based company said it had profit of 3 cents per share. Earnings, adjusted for stock option expense, came to 6 cents per share. The biotechnology company posted revenue of $22.2 million in the ...

  • CTI BioPharma Reports Second Quarter 2017 Financial Results
    PR Newswire4 months ago

    CTI BioPharma Reports Second Quarter 2017 Financial Results

    -PAC203 Phase 2 Trial of Pacritinib Initiated -Marketing Authorization Application for Pacritinib Under Review by European Medicines Agency -Enrollment Completed in the PIX306 Phase 3 Trial of PIXUVRI® ...

  • ACCESSWIRE4 months ago

    Investor Network: CTI BioPharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 3, 2017 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM Eastern ...

  • CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
    PR Newswire4 months ago

    CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma

    SEATTLE, Aug. 2, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced the completion of enrollment in the Phase 3 PIX306 trial of PIXUVRI® (pixantrone). The PIX306 trial is evaluating PIXVURI combined with rituximab in comparison to that of rituximab combined with gemcitabine in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). Patients eligible to be enrolled in the trial had failed front line CHOP-R and were not eligible for autologous stem cell transplant (ASCT) (2nd line) or failed ASCT (3rd or 4th line).

  • CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
    PR Newswire4 months ago

    CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib

    SEATTLE, Aug. 1, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that the first patient has been enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. PAC203 is designed to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in the Phase 3 PERSIST-2 trial of pacritinib in patients with myelofibrosis.

  • CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
    PR Newswire4 months ago

    CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017

    SEATTLE , July 27, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its second quarter 2017 financial results on Thursday, ...

  • CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
    PR Newswire4 months ago

    CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors

    SEATTLE, July 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed a Director of CTI BioPharma effective July 21, 2017. Dr. Fischer  has more than 20 years experience in developing and commercializing novel medicines in the biopharmaceutical industry and currently serves as liver therapeutic area head at Allergan following its acquisition of Tobira Therapeutics in 2016 where he previously served as Chief Executive Officer.

  • CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
    PR Newswire4 months ago

    CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia

    SEATTLE, July 13, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). Validation confirms that the submission is complete and initiates the centralized review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).  The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on EU authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 EU member states.

  • PR Newswire5 months ago

    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    SEATTLE , June 15, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to ...

  • CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
    PR Newswire6 months ago

    CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock

    SEATTLE, June 6, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the "Offering"). Each share of Series N-3 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $3.00  per share of common stock, for a total of approximately 15.0 million shares of common stock.

  • CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
    PR Newswire6 months ago

    CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock

    SEATTLE, June 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-3 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-3 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance and subject to certain limitations, into shares of common stock. CTI plans to use the net proceeds from this Offering to conduct the PAC203 clinical trial, submit a new Marketing Authorization Application for pacritinib to the European Medicines Agency, conduct additional research concerning the possible application of pacritinib in indications outside of myelofibrosis, and complete the PIX306 clinical trial, as well as for general corporate purposes, which may include funding research and development, conducting preclinical and clinical trials, acquiring or in-licensing potential new pipeline candidates, preparing and filing possible new drug applications and general working capital.

  • CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations
    PR Newswire6 months ago

    CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations

    SEATTLE, June 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that David R. Parkinson, M.D., has been appointed a Director of CTI BioPharma effective June 5, 2017. Dr. Parkinson has more than 20 years in oncology clinical development with executive leadership roles at major biotechnology and pharmaceutical companies. Additionally, Phillip M. Nudelman, Ph.D., has resigned as a member of the Board of Directors due to health reasons.

  • Associated Press7 months ago

    CTI BioPharma reports 1Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 71 cents. Losses, adjusted for stock option expense, came to 65 cents per share. The biotechnology company posted revenue of $754,000 ...

  • CTI BioPharma Reports First Quarter 2017 Financial Results
    PR Newswire7 months ago

    CTI BioPharma Reports First Quarter 2017 Financial Results

    SEATTLE, May 3, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2017. Recent Highlights In April 2017, CTI BioPharma ...

  • Capital Cube7 months ago

    CTI BioPharma Corp. – Value Analysis (MILAN:CTIC) : April 28, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives CTI BioPharma Corp. a score of 25. Our analysis is based on comparing CTI BioPharma Corp. with the following peers – Nigerian-German Chemicals Plc, Nanologica AB, NeuroSearch A/S and El-Nile Co. for Pharmaceuticals & Chemical Industries (NIG.GERMAN-NG, NICA-SE, NEUR-DK and NIPH-EG). Investment Outlook CTI BioPharma Corp. has ... Read more (Read more...)

  • CTI BioPharma Corp. breached its 50 day moving average in a Bearish Manner : CTIC-IT : April 27, 2017
    Capital Cube7 months ago

    CTI BioPharma Corp. breached its 50 day moving average in a Bearish Manner : CTIC-IT : April 27, 2017

    Categories: Europe Stock Alerts Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for CTI BioPharma Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)